Baader Bank Aktiengesellschaft acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,252 shares of the biopharmaceutical company’s stock, valued at approximately $566,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Private Wealth Management Group LLC bought a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Palisade Asset Management LLC bought a new position in Gilead Sciences during the 1st quarter worth approximately $29,000. Sachetta LLC bought a new position in Gilead Sciences during the 4th quarter worth approximately $30,000. Rakuten Securities Inc. bought a new position in Gilead Sciences during the 4th quarter worth approximately $33,000. Finally, Gladius Capital Management LP bought a new position in Gilead Sciences during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
Gilead Sciences Price Performance
Shares of GILD stock traded up $0.20 during trading on Thursday, hitting $74.34. The company had a trading volume of 5,194,900 shares, compared to its average volume of 7,335,189. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The stock’s 50-day moving average is $70.41 and its two-hundred day moving average is $70.32. The stock has a market capitalization of $92.62 billion, a price-to-earnings ratio of 205.89, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86.
Gilead Sciences Announces Dividend
Analysts Set New Price Targets
GILD has been the subject of several research analyst reports. Maxim Group lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $71.00 to $72.00 and gave the company a “sector perform” rating in a research note on Friday, August 9th. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective for the company in a research note on Monday, July 8th. Robert W. Baird reissued a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research report on Thursday, June 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Twelve investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.94.
Get Our Latest Stock Report on GILD
Insiders Place Their Bets
In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- What is the FTSE 100 index?
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- 3 Fintech Stocks With Good 2021 Prospects
- Jeff Brown’s Exegesis AI Stock Picks
- Election Stocks: How Elections Affect the Stock Market
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.